Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Global Value Dossier

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial

The severe asthma drug met both of the late-stage study’s co-primary endpoints

- PMLiVE

WHO announces priority endemic pathogens for urgent vaccine development

The study identifies the 17 pathogens that regularly cause diseases in communities

- PMLiVE

UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

- PMLiVE

NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

Systemic mastocytosis affects approximately one in every 10,000 people in the UK

- PMLiVE

Medscape Publication is Awarded Poster of Distinction at AASLD

Medscape Education is committed to disseminating the outcomes of the education programs through peer-reviewed publications and posters at leading medical conferences around the world. To this end, Medscape publishes more...

Medscape Education

- PMLiVE

Advancing Education at AASLD 2024

Get ready for an exciting experience at AASLD 2024! The Medscape team is thrilled to be in San Diego from November 15-19 for this year’s AASLD conference, where we will...

Medscape Education

- PMLiVE

Infographic: Advantages & Disadvantages of Different Meeting Formats

Discover the unique pros and cons of in-person, hybrid, synchronous virtual, and asynchronous virtual meetings with our detailed infographic. Perfect for anyone planning efficient and engaging meetings, especially in pharmaceutical...

Impetus Digital

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases

- PMLiVE

Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study

The trial is evaluating OHB-607 for preventing bronchopulmonary dysplasia and other complications

- PMLiVE

Johnson & Johnson’s Balversa granted MHRA approval in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links